Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (BNTX) and Cardinal Health (CAH)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioNTech SE (BNTX – Research Report) and Cardinal Health (CAH – Research Report).

BioNTech SE (BNTX)

Morgan Stanley analyst Terence Flynn maintained a Hold rating on BioNTech SE today and set a price target of $109.00. The company’s shares closed last Thursday at $94.51, close to its 52-week low of $88.00.

According to TipRanks.com, Flynn is a 5-star analyst with an average return of 10.5% and a 62.8% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Vertex Pharmaceuticals, and Crispr Therapeutics AG.

Currently, the analyst consensus on BioNTech SE is a Hold with an average price target of $119.33, representing a 25.8% upside. In a report issued on January 25, TD Cowen also maintained a Hold rating on the stock with a $101.00 price target.

See the top stocks recommended by analysts >>

Cardinal Health (CAH)

In a report released today, Erin Wright from Morgan Stanley maintained a Buy rating on Cardinal Health, with a price target of $117.00. The company’s shares closed last Thursday at $105.10, close to its 52-week high of $111.40.

According to TipRanks.com, Wright is a 5-star analyst with an average return of 16.6% and a 68.9% success rate. Wright covers the Healthcare sector, focusing on stocks such as Elanco Animal Health, Patterson Companies, and Idexx Laboratories.

Cardinal Health has an analyst consensus of Hold, with a price target consensus of $113.00, implying an 8.7% upside from current levels. In a report issued on January 29, UBS also maintained a Buy rating on the stock with a $122.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BNTX:

• BioNTech and Duality announce FDA Fast track designation for BNT325/DB-1305
• BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
• BioNTech price target lowered to $107 from $133 at H.C. Wainwright
• BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
• BioNTech and Duality Biologics begin Phase 3 trial of breast cancer candidate